Kenneth J. Mandell, MD, PhD, highlights the potential benefits of incorporating drug-eluting IOLs into future practice, including the OcuRing-K (LayerBio), a single, nonsteroidal, sustained-release implant.
Kenneth J. Mandell, MD, PhD, highlights the potential benefits of incorporating drug-eluting IOLs into future practice, including the OcuRing-K (LayerBio), a single, nonsteroidal, sustained-release implant.
I have wondered about this concept for many many years. Makes a LOT of sense to me. Drug-eluting stents (DES) have been in clinical use in Cardiology for over a decade! Why is surgical Ophthalmology so far behind Cardiology?
Please log in to leave a comment.
Comments
Just Now
Stephen Orr
1 year ago
I have wondered about this concept for many many years. Makes a LOT of sense to me. Drug-eluting stents (DES) have been in clinical use in Cardiology for over a decade! Why is surgical Ophthalmology so far behind Cardiology?